NCT00172107 - A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

May 18, 1995

Primary Completion Date

March 24, 1997

Study Completion Date

March 24, 1997

Conditions

Osteoporosis

Interventions

DRUG

ALX1-11 50 mcg

PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen

DRUG

placebo

placebo powder for subcutaneous injection

DRUG

ALX1-11 75mcg

PTH(1-84)75 mcg for subcutaneous injection

DRUG

ALX1-11

PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen

Trial Locations (19)

10993

Helen Hayes Hospital, West Haverstraw

20817

'Bethesda Health Research Center, Bethesda

34996

Radiant Research, Stuart, Stuart

75235

Radiant Research, Dallas, Dallas

78229

'Diabetes & Glandular Disease Research Associates, P.A., San Antonio

78758

Simona Scumpia, Austin

80227

Paul Miller, Lakewood

80501

Longmont Medical Research Network, Longmont

85381

Pivotal Research, Peoria

90404

John Wayne Cancer Institute, Santa Monica

92354

Loma Linda Osteoporosis Research Clinic, Loma Linda

94941

Steven Harris, Mill Valley

97213

Oregon Osteoporosis Center, Portland

98104

Northwest Lipid Research Center, Seattle

04401

Maine Center for Osteoporosis Research and Education of St. Joseph's Hospital, Bangor

T2N 4N1

Heritage Medical Research Clinic, Calgary

V5Z 2N6

Osteoporosis Research Center, Vancouver

B3H 1V7

Capital Health Centre, Halifax

N6A 4V2

St. Joseph's Health Center, London